Seres Therapeutics to Discuss SER-155 irEC Trial Results on July 8

Seres Therapeutics announced it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155. The trial focuses on patients with immune checkpoint inhibitor-related enterocolitis (irEC), a serious side effect of cancer therapy. The webcast is scheduled for July 8, 2026, at 8:30 am ET, and will detail SER-155's potential as an immunosuppressive-free treatment to prevent interruption of cancer therapy. The IST involved 15 participants with moderate to severe irEC, with a primary endpoint of immunosuppressive-free clinical response by Day 15.